PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2019; 79(08): 844-853
DOI: 10.1055/a-0854-6472
GebFra Science
Review/Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Progesteron zur Prävention der Frühgeburt – ein Update evidenzbasierter Indikationen

Artikel in mehreren Sprachen: English | deutsch
Ruben-J. Kuon‡
1   Universitätsklinikum Heidelberg, Abteilung für Gynäkologische Endokrinologie und Fertilitätsstörungen, Frauenklinik, Heidelberg, Germany
,
Pauline Voß
1   Universitätsklinikum Heidelberg, Abteilung für Gynäkologische Endokrinologie und Fertilitätsstörungen, Frauenklinik, Heidelberg, Germany
,
Werner Rath‡
2   Medizinische Fakultät Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 09. Dezember 2018
revised 05. Februar 2019

accepted 10. Februar 2019

Publikationsdatum:
12. August 2019 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Die Prävention und Behandlung der Frühgeburt stellt nach wie vor eine der größten Herausforderungen in der Geburtshilfe dar. Weltweit werden 11% aller Kinder zu früh geboren mit weitreichenden Konsequenzen für die betroffenen Kinder, ihre Familien und das Gesundheitssystem. Experimentelle Studien weisen darauf hin, dass Progesteron uterine Kontraktionen hemmt, die Cervix uteri stabilisiert und immunmodulatorisch wirksam ist. In den letzten Jahren ist eine Vielzahl von klinischen Studien, die Gestagene zur Prävention der Frühgeburt einsetzen, publiziert worden. Die Vergleichbarkeit dieser Studien untereinander ist durch unterschiedliche Einschlusskriterien, Anwendung verschiedener Gestagene sowie deren Applikationsmodi schwierig. Es wurde daher im Rahmen einer Literaturrecherche (1956 bis 09/2018) eine kritische Evaluation der Studienlage durchgeführt. Unter Berücksichtigung der neuesten randomisierten kontrollierten Studien ergeben sich folgende evidenzbasierte Empfehlungen: Bei asymptomatischen Frauen mit Einlingsschwangerschaften und sonografisch verkürzter Zervix ≤ 25 mm vor der 24. Schwangerschaftswoche (SSW) führt die tägliche Gabe von Progesteron vaginal (200 mg Kapsel oder 90 mg Gel) bis zur 36 + 6 SSW zu einer signifikanten Reduktion der Frühgeburtenrate und einer Verbesserung des neonatalen Outcomes. Neueste Daten weisen auch auf positive Effekte einer Behandlung mit Progesteron bei Geminischwangerschaften und einer sonografisch verkürzten Zervix ≤ 25 mm vor der 24. SSW hin. Dagegen ist die Studienlage für die Gabe von Progesteron bei Frauen mit Einlingsschwangerschaft mit vorausgegangener Frühgeburt deutlich uneinheitlicher geworden. Für diese Indikation kann derzeit keine generelle Empfehlung ausgesprochen werden, sie ist daher eine Einzelfallentscheidung. Auch wenn der Einsatz von Progesteron im Hinblick auf mögliche Langzeitfolgen als sicher gilt, sollte eine nicht indizierte Exposition vermieden werden. Entscheidend für den Therapieerfolg ist die präzise Selektion der Schwangeren.

Schlüsselwörter

Frühgeburt - Progesteron - 17-α-Hydroxyprogesteroncaproat - Zervixlänge
 

  • References/Literatur

  • 1 Blencowe H, Cousens S, Chou D. et al. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health 2013; 10 (Suppl. 01) S2
    CrossrefPubMedGoogle Scholar
  • 2 IQTIG. Bundesauswertung zum Erfassungsjahr 2017 – Geburtshilfe Qualitätsindikatoren. Online: https://iqtig.org/downloads/auswertung/2017/16n1gebh/QSKH_16n1-GEBH_2017_BUAW_V02_2018-08-01.pdf last access: 31.03.2019
    PubMedGoogle Scholar
  • 3 Vogel JP, Chawanpaiboon S, Moller AB. et al. The global epidemiology of preterm birth. Best Pract Res Clin Obstet Gynaecol 2018; 52: 3-12
    CrossrefPubMedGoogle Scholar
  • 4 Rotteveel J, van Weissenbruch MM, Twisk JWR. et al. Infant and childhood growth patterns, insulin sensitivity, and blood pressure in prematurely born young adults. Pediatrics 2008; 122: 313-321
    CrossrefPubMedGoogle Scholar
  • 5 Lindström K, Winbladh B, Haglund B. et al. Preterm infants as young adults: a Swedish national cohort study. Pediatrics 2007; 120: 70-77
    CrossrefPubMedGoogle Scholar
  • 6 Goldenberg RL, Culhane JF, Iams JD. et al. Epidemiology and causes of preterm birth. Lancet 2008; 371: 75-84
    CrossrefPubMedGoogle Scholar
  • 7 Rath W, Kehl S. Acute Tocolysis – a Critical Analysis of Evidence-Based Data. Geburtsh Frauenheilk 2018; 78: 1245-1255
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 8 Kyvernitakis I, Maul H, Bahlmann F. Controversies about the Secondary Prevention of Spontaneous Preterm Birth. Geburtsh Frauenheilk 2018; 78: 585-595
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 9 Ruddock NK, Shi S-Q, Jain S. et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol 2008; 199: 391.e1-391.e7
    CrossrefPubMedGoogle Scholar
  • 10 Garfield RE, Saade G, Buhimschi C. et al. Control and assessment of the uterus and cervix during pregnancy and labour. Hum Reprod Update 1998; 4: 673-695
    CrossrefPubMedGoogle Scholar
  • 11 Furcron AE, Romero R, Plazyo O. et al. Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface. Am J Obstet Gynecol 2015; 213: 846.e1-846.e19
    CrossrefPubMedGoogle Scholar
  • 12 Kuon RJ, Shi S-Q, Maul H. et al. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle. Am J Obstet Gynecol 2010; 202: 455.e1-455.9
    CrossrefPubMedGoogle Scholar
  • 13 Ananth CV, Getahun D, Peltier MR. et al. Recurrence of spontaneous versus medically indicated preterm birth. Am J Obstet Gynecol 2006; 195: 643-650
    CrossrefPubMedGoogle Scholar
  • 14 OʼBrien JM, Adair CD, Lewis DF. et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 687-696
    CrossrefPubMedGoogle Scholar
  • 15 Crowther CA, Ashwood P, McPhee AJ. et al. Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial. PLoS Med 2017; 14: e1002390
    CrossrefPubMedGoogle Scholar
  • 16 Norman JE, Marlow N, Messow CM. et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet 2016; 387: 2106-2116
    CrossrefPubMedGoogle Scholar
  • 17 Ashoush S, El-Kady O, Al-Hawwary G. et al. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial. Acta Obstet Gynecol Scand 2017; 96: 1460-1466
    CrossrefPubMedGoogle Scholar
  • 18 Onsrud M, Paus E, Haug E. et al. Intramuscular Administration of Hydroxyprogesterone Caproate in patients with Endometrial Carcinoma: Pharmacokinetics and effects on adrenal function. Acta Obstet Gynecol Scand 1985; 64: 519-523
    CrossrefPubMedGoogle Scholar
  • 19 Romero R, Yeo L, Miranda J. et al. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J Perinat Med 2013; 41: 27-44
    PubMedGoogle Scholar
  • 20 Maher MA, Abdelaziz A, Ellaithy M. et al. Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone. Acta Obstet Gynecol Scand 2013; 92: 215-222
    CrossrefPubMedGoogle Scholar
  • 21 Elimian A, Smith K, Williams M. et al. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth. Int J Gynaecol Obstet 2016; 134: 169-172
    CrossrefPubMedGoogle Scholar
  • 22 Bafghi AST, Bahrami E, Sekhavat L. Comparative Study of Vaginal versus Intramuscular Progesterone in the Prevention of Preterm Delivery: A Randomized Clinical Trial. Electron Physician 2015; 7: 1301-1309
    PubMedGoogle Scholar
  • 23 Saccone G, Khalifeh A, Elimian A. et al. Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol 2017; 49: 315-321
    CrossrefPubMedGoogle Scholar
  • 24 Oler E, Eke AC, Hesson A. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery. Int J Gynaecol Obstet 2017; 138: 12-16
    CrossrefPubMedGoogle Scholar
  • 25 Dodd JM, Jones L, Flenady V. et al. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev 2013; (07) CD004947
    PubMedGoogle Scholar
  • 26 Dodd JM, Grivell RM, OBrien CM. et al. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. Cochrane Database Syst Rev 2017; (10) CD012024
    PubMedGoogle Scholar
  • 27 Serra V, Perales A, Meseguer J. et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. BJOG 2013; 120: 50-57
    CrossrefPubMedGoogle Scholar
  • 28 Rust OA, Atlas RO, Kimmel S. et al. Does the presence of a funnel increase the risk of adverse perinatal outcome in a patient with a short cervix?. Am J Obstet Gynecol 2005; 192: 1060-1066
    CrossrefPubMedGoogle Scholar
  • 29 Romero R, Conde-Agudelo A, da Fonseca E. et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol 2018; 218: 161-180
    CrossrefPubMedGoogle Scholar
  • 30 Romero R, Nicolaides KH, Conde-Agudelo A. et al. Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol 2016; 48: 308-317
    CrossrefPubMedGoogle Scholar
  • 31 Fonseca EB, Celik E, Parra M. et al. Progesterone and the Risk of Preterm Birth among Women with a Short Cervix. N Engl J Med 2007; 357: 462-469
    CrossrefPubMedGoogle Scholar
  • 32 DeFranco EA, OʼBrien JM, Adair CD. et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 697-705
    CrossrefPubMedGoogle Scholar
  • 33 Cetingoz E, Cam C, Sakallı M. et al. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial. Arch Gynecol Obstet 2011; 283: 423-429
    CrossrefPubMedGoogle Scholar
  • 34 Hassan SS, Romero R, Vidyadhari D. et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011; 38: 18-31
    CrossrefPubMedGoogle Scholar
  • 35 McNamara HC, Wood R, Chalmers J. et al. STOPPIT Baby Follow-up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS One 2015; 10: e0122341
    CrossrefPubMedGoogle Scholar
  • 36 Vedel C, Larsen H, Holmskov A. et al. Long-term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound Obstet Gynecol 2016; 48: 382-389
    CrossrefPubMedGoogle Scholar
  • 37 Combs CA. Vaginal progesterone for asymptomatic cervical shortening and the case for universal screening of cervical length. Am J Obstet Gynecol 2012; 206: 101-103
    CrossrefPubMedGoogle Scholar
  • 38 Khalifeh A, Berghella V. Universal cervical length screening in singleton gestations without a previous preterm birth: ten reasons why it should be implemented. Am J Obstet Gynecol 2016; 214: 603.e1-603.e5
    CrossrefPubMedGoogle Scholar
  • 39 Campbell S. Universal cervical-length screening and vaginal progesterone prevents early preterm births, reduces neonatal morbidity and is cost saving: doing nothing is no longer an option. Ultrasound Obstet Gynecol 2011; 38: 1-9
    PubMedGoogle Scholar
  • 40 Kuon RJ, Abele H, Berger R. et al. [Progesterone for Prevention of Preterm Birth–Evidence-based Indications]. Z Geburtshilfe Neonatol 2015; 219: 125-135
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 41 Conde-Agudelo A, Romero R. Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: clinical and public health implications. Am J Obstet Gynecol 2016; 214: 235-242
    CrossrefPubMedGoogle Scholar
  • 42 Pedretti MK, Kazemier BM, Dickinson JE. et al. Implementing universal cervical length screening in asymptomatic women with singleton pregnancies: challenges and opportunities. Aust N Z J Obstet Gynaecol 2017; 57: 221-227
    CrossrefPubMedGoogle Scholar
  • 43 Goodnight W. Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016. Am J Perinatol 2016; 33: 253-257
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 44 Vintzileos AM, Visser GHA. Interventions for women with mid-trimester short cervix: which ones work?. Ultrasound Obstet Gynecol 2017; 49: 295-300
    CrossrefPubMedGoogle Scholar
  • 45 Newnham JP, Kemp MW, White SW. et al. Applying Precision Public Health to Prevent Preterm Birth. Front Public Health 2017; 5: 66
    PubMedGoogle Scholar
  • 46 Fonseca EB, Celik E, Parra M. et al. Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007; 357: 462-469
    CrossrefPubMedGoogle Scholar
  • 47 Rode L, Klein K, Nicolaides KH. et al. for the PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011; 38: 272-280
    PubMedGoogle Scholar
  • 48 El-Refaie W, Abdelhafez MS, Badawy A. Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet 2015; 293: 61-67
    PubMedGoogle Scholar
  • 49 Brizot ML, Hernandez W, Liao AW. et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2015; 213: 82.e1-82.e9
    CrossrefPubMedGoogle Scholar
  • 50 Romero R, Conde-Agudelo A, El-Refaie W. et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol 2017; 49: 303-314
    CrossrefPubMedGoogle Scholar
  • 51 Meis PJ, Klebanoff M, Thom E. et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385
    CrossrefPubMedGoogle Scholar
  • 52 Northen AT, Norman GS, Anderson K. et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007; 110: 865-872
    CrossrefPubMedGoogle Scholar
  • 53 Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol 2011; 4: 60-72
    PubMedGoogle Scholar
  • 54 Friedler S. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod 1999; 14: 1944-1948
    CrossrefPubMedGoogle Scholar
  • 55 Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol 2011; 4: 60-72
    PubMedGoogle Scholar
  • 56 De Ziegler D, Bulletti C, De Monstier B. et al. The first uterine pass effect. Ann N Y Acad Sci 1997; 828: 291-299
    CrossrefPubMedGoogle Scholar
  • 57 Levy T. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. Steroids 2000; 65: 645-649
    CrossrefPubMedGoogle Scholar
  • 58 OʼBrien JM, Lewis DF. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety. Am J Obstet Gynecol 2016; 214: 45-56
    CrossrefPubMedGoogle Scholar
  • 59 Ahn KH, Bae NY, Hong SC. et al. The safety of progestogen in the prevention of preterm birth: meta-analysis of neonatal mortality. J Perinat Med 2017; 45: 11-20
    PubMedGoogle Scholar
  • 60 da Fonseca EB, Bittar RE, de Carvalho MH. et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419-424
    CrossrefPubMedGoogle Scholar
  • 61 Azargoon A, Ghorbani R, Aslebahar F. Vaginal progesterone on the prevention of preterm birth and neonatal complications in high risk women: A randomized placebo-controlled double-blind study. Int J Reprod Biomed (Yazd) 2016; 14: 309-316
    PubMedGoogle Scholar
  • 62 Rai P, Rajaram S, Goel N. et al. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009; 104: 40-43
    CrossrefPubMedGoogle Scholar
  • 63 Glover MM, McKenna DS, Downing CM. et al. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol 2011; 28: 377-381
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 64 Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012; 206: 376-386
    CrossrefPubMedGoogle Scholar
  • 65 Society for Maternal-Fetal Medicine Publications Committee. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. Am J Obstet Gynecol 2017; 216: B11-B13
    CrossrefPubMedGoogle Scholar
  • 66 Lim AC, Hegeman MA, Huis In ʼT Veld MA. et al. Cervical length measurement for the prediction of preterm birth in multiple pregnancies: a systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol 2011; 38: 10-17
    PubMedGoogle Scholar
  • 67 Roman A, Da Silva Costa F, Araujo Júnior E. et al. Rescue Adjuvant Vaginal Progesterone May Improve Outcomes in Cervical Cerclage Failure. Geburtsh Frauenheilk 2018; 78: 785-790
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 68 Winer N, Bretelle F, Senat MV. et al. Groupe de Recherche en Obstétrique et Gynécologie. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial. Am J Obstet Gynecol 2015; 212: 485.e1-485.e10
    CrossrefPubMedGoogle Scholar